iBio, Inc.
iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence ( AI ) for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space. Our core mission is to harness the potential of AI and machine learning ( ML ) to unveil novel biologics which other scie…
$0.77
-$0.01 (-1.28%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-35141.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 75.0% YoY. Margins deteriorated 30490.5pp alongside, both lines moving the wrong way.
Negative free cash flow of -$24M. The business is consuming cash, not generating it. Operating margin contracted 30490.5pp YoY, cost discipline may be slipping.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$100K
▼ -75.0% YoY
Net Income (TTM)
-$33M
▼ -79.8% YoY
Op. Margin
-35141.00%
▼ -30490.5pp YoY
ROIC
-52.23%
▲ +15.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$24M
▼ -55.3% YoY
Op. Cash Flow (TTM)
-$23M
▼ -51.7% YoY
Net Debt
-$86M
Net Cash Position
Cash & Equiv.
$88M
5Y CAGR: -46.9%
Continue Research
SourceComputed from the 10-Q filed 27 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is iBio (IBIO) overvalued?
iBio (IBIO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, iBio scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is iBio a high-quality business?+
iBio scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -35,141.0% operating margin and a -52.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is iBio a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh IBIO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.